Lodoxamide Datasheet DC Chemicals
Target Home > Products > Featured products
Cat.No DC10188
Name Lodoxamide

Chemical Properties

CAS 53882-12-5
Formula C11N3O6CLH6
MW 311.6348
Storage 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological activity

Description CAS NO.:53882-12-5
Product Name:Lodoxamide
Synonyms:Lodoxamide;2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid;Acetic acid,2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxo;Alomide (TN);diesters of N,N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid;Lodoxamida;Lodoxamida [INN-Spanish];Lodoxamidum;Lodoxamidum [INN-Latin];N,N'-(2-Chlor-5-cyan-3-phenylen)dioxamsaeure;N,N'-(2-Chlor-5-cyan-m-phenylen)-dioxamsaeure;N-N'-(2-chloro-5-cyano-m-phenylene)dioxamic acid;UNII-SPU695OD73;2,2′-[(2-Chloro-5-cyano-1,3-phenylene)diimino]bis-2-oxoacetic acid
EINEC:
Molecular Formula:C11N3O6CLH6
Molecular Weight:311.6348
Target:
In Vivo Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys[1]. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance[3]. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep[4].
In Vitro Lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells[1]. The chemotactic response of eosinophils to fMLP as well as to IL-5 is significant and dose-dependent inhibited by Lodoxamide. Lodoxamide is also able to strongly inhibit the release of eosinophil peroxidase after IgA-dependent activation and, to a lesser extent, the release of eosinophil cationic protein and eosinophil-derived neurotoxin[2].
Kinase Assay
Cell Assay
Animal Administration

References

Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com